E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments

Scientific Reports
Wenjun LanJuan Iovanna

Abstract

The main goal of this study was to find out strategies of clinical relevance to classify patients with a pancreatic ductal adenocarcinoma (PDAC) for individualized treatments. In the present study a set of 55 patient-derived xenografts (PDX) were obtained and their transcriptome were analyzed by using an Affymetrix approach. A supervised bioinformatics-based analysis let us to classify these PDX in two main groups named E2F-highly dependent and E2F-lowly dependent. Afterwards their characterization by using a Kaplan-Meier analysis demonstrated that E2F high patients survived significantly less than E2F low patients (9.5 months vs. 16.8 months; p = 0.0066). Then we tried to establish if E2F transcriptional target levels were associated to the response to cytotoxic treatments by comparing the IC50 values of E2F high and E2F low cells after gemcitabine, 5-fluorouracil, oxaliplatin, docetaxel or irinotecan treatment, and no association was found. Then we identified an E2F inhibitor compound, named ly101-4B, and we observed that E2F-higly dependent cells were more sensitive to its treatment (IC50 of 19.4 ± 1.8 µM vs. 44.1 ± 4.4 µM; p = 0.0061). In conclusion, in this work we describe an E2F target expression-based classification tha...Continue Reading

References

Jun 1, 1990·Cell·E R Fearon, B Vogelstein
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Aug 8, 1998·Genes & Development·N Dyson
Oct 30, 2001·Behavioural Brain Research·Y BenjaminiI Golani
Apr 16, 2002·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Walter M KleinRobb E Wilentz
May 3, 2003·Cancer Cell·Hugh Cam, Brian David Dynlacht
Nov 25, 2003·The EMBO Journal·Luisa Di StefanoKristian Helin
Aug 5, 2008·Cancer Research·Yihong MaW Douglas Cress
Oct 24, 2009·Nature Reviews. Cancer·Hui-Zi ChenGustavo Leone
Sep 11, 2010·Bioorganic & Medicinal Chemistry Letters·Menghua WangLing Peng
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Oct 30, 2014·Nucleic Acids Research·Damian SzklarczykChristian von Mering
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 16, 2016·Cell Systems·Arthur LiberzonPablo Tamayo
Feb 18, 2016·Genes & Development·Haoqiang YingRonald A DePinho
Feb 26, 2016·Nature·Peter BaileySean M Grimmond
Mar 1, 2016·Oncogene·J JohnsonR Bernards
Jan 28, 2017·Nature Reviews. Cancer·Tobias Otto, Piotr Sicinski
Aug 16, 2017·Cancer Cell·UNKNOWN Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, UNKNOWN Cancer Genome Atlas Research Network

❮ Previous
Next ❯

Citations

Aug 23, 2020·Cancers·Kanchan VishnoiBasabi Rana
May 6, 2019·Nature Reviews. Cancer·Lindsey N Kent, Gustavo Leone
Feb 6, 2020·Médecine sciences : M/S·Nelson Dusetti, Juan Iovanna
Feb 18, 2020·CNS Neuroscience & Therapeutics·Hai YuMaode Wang

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE55513
GSE89792

Methods Mentioned

BETA
xenografts
xenograft
biopsies
chip

Clinical Trials Mentioned

NCT01692873

Software Mentioned

GeneChip
GraphPad
IPA
GraphPad Prism
ArrayTools
Affymetrix
GSEA
STRING
GENE

Related Concepts

Related Feeds

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.